172 related articles for article (PubMed ID: 34737393)
21. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
22. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
23. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
24. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
25. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
Bian J; Sun X; Li B; Ming L
Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
[TBL] [Abstract][Full Text] [Related]
27. The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.
Abdalla N; Pazura M; Słomka A; Piórkowski R; Sawicki W; Cendrowski K
Ginekol Pol; 2016; 87(12):781-786. PubMed ID: 28098927
[TBL] [Abstract][Full Text] [Related]
28. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
29. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
[TBL] [Abstract][Full Text] [Related]
30. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
31. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
32. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
33. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
34. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
35. The Utility of Preoperative Serum CA125 Combined with HE4 to Predict Lymph Node Metastasis in Endometrial Cancer.
Prueksaritanond N; Angsathapon S; Insin P
Gynecol Obstet Invest; 2023; 88(1):53-60. PubMed ID: 36596280
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of serum HE4 level in the management of endometrial cancer: A pilot study.
Rajadevan N; McNally O; Neesham D; Richards A; Naaman Y
Aust N Z J Obstet Gynaecol; 2021 Apr; 61(2):284-289. PubMed ID: 33528032
[TBL] [Abstract][Full Text] [Related]
37. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J
BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794
[TBL] [Abstract][Full Text] [Related]
38. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
Zhang Y; Qiao C; Li L; Zhao X; Li Y
Afr Health Sci; 2014 Dec; 14(4):913-8. PubMed ID: 25834501
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.
Omer B; Genc S; Takmaz O; Dirican A; Kusku-Kiraz Z; Berkman S; Gurdol F
Tumour Biol; 2013 Oct; 34(5):2645-50. PubMed ID: 23640061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
